Figure 2 illustrates a significant reduction in BCL2 expression level was reported upon treatment of HepG2 cells with the standard anticancer drug doxorubicin in a concentration of 200 μmole or with sitagliptin (IC50: 89 μM; or IC35; 62.5 μM) to reach 44%, 43%, and 58%, respectively, as compared to the negative control, untreated cancer cells. This evidence concerns the gene BCL2 and cancer.